journal article·2023-07Open access

Interplay between Liposomes and IgM: Principles, Challenges, and Opportunities

Huan Wang, Shiqi Lin, Xiying Wu, Kuan Jiang, Huiping Lu, Changyou Zhan

Advanced Science· Volume 10· Issue 20

Abstract

Abstract Liposomes have received tremendous attention as a class of versatile pharmaceutical vehicles of great potential over the past several decades. However, the application of liposomes encounters major challenges due to the knowledge gaps in their in vivo delivery process. Immunoglobulin M (IgM) displays both pervasiveness and complexity in regulating the biological functions as well as eliciting adverse effects of liposomes. Understanding, mitigating, and exploiting the duality of IgM are prerequisites for achieving various biomedical applications of liposomes. In this review, the intricate relationship between liposomes and their biological environments has been summarized, with an emphasis on the regulatory effects of IgM on in vivo performance of liposomes. Corresponding solutions have also been discussed to evade IgM‐mediated opsonization for safe and efficient drug delivery.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Monoclonal and Polyclonal Antibodies Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy Naval Medical University Shanghai 200433 P. R. China

Department of Pharmacy, Shanghai Pudong Hospital, Fudan University Pudong Medical Center & Department of Pharmacology School of Basic Medical Sciences Fudan University Shanghai 201399 P. R. China

Shanghai Skin Disease Hospital Tongji University School of Medicine Shanghai 200443 China

Shanghai Engineering Research Center for Synthetic Immunology Fudan University Shanghai 200032 P. R. China

Funding

National Natural Science Foundation of China · Ministry of Science and Technology

References (100+)

Show source-provided references
1. 10.1016/S0022-2836(64)80115-710.1016/S0022-2836(64)80115-7 ↗
2. 10.1038/s41416-018-0235-210.1038/s41416-018-0235-2 ↗
3. 10.1016/j.drudis.2021.05.01010.1016/j.drudis.2021.05.010 ↗
4. 10.1016/j.addr.2021.11385110.1016/j.addr.2021.113851 ↗
5. 10.1016/j.apsb.2021.04.01010.1016/j.apsb.2021.04.010 ↗
6. 10.1016/j.jconrel.2012.03.02010.1016/j.jconrel.2012.03.020 ↗
7. 10.1158/1078-0432.CCR-18-299010.1158/1078-0432.CCR-18-2990 ↗
8. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
9. 10.1080/14686996.2019.162717410.1080/14686996.2019.1627174 ↗
10. 10.1021/jacs.2c0227710.1021/jacs.2c02277 ↗
11. 10.1002/wnan.161510.1002/wnan.1615 ↗
12. 10.1038/nnano.2017.6110.1038/nnano.2017.61 ↗
13. 10.1021/acsnano.7b0800810.1021/acsnano.7b08008 ↗
14. 10.1007/s00204-016-1797-510.1007/s00204-016-1797-5 ↗
15. 10.1039/C5NR09158F10.1039/C5NR09158F ↗
16. 10.1002/adma.20180333510.1002/adma.201803335 ↗
17. 10.1021/acs.biomac.9b0053910.1021/acs.biomac.9b00539 ↗
18. 10.1021/acs.nanolett.1c0394610.1021/acs.nanolett.1c03946 ↗
19. 10.1021/acsnano.5b0330010.1021/acsnano.5b03300 ↗
20. 10.1016/j.jconrel.2020.01.01810.1016/j.jconrel.2020.01.018 ↗
21. 10.1159/00023330910.1159/000233309 ↗
22. 10.1016/j.jim.2019.11266910.1016/j.jim.2019.112669 ↗
23. 10.1517/17425247.2012.72096910.1517/17425247.2012.720969 ↗
24. 10.1016/j.jconrel.2016.06.04010.1016/j.jconrel.2016.06.040 ↗
25. 10.1021/acs.analchem.6b0343710.1021/acs.analchem.6b03437 ↗
26. 10.1038/s41467-017-00622-410.1038/s41467-017-00622-4 ↗
27. 10.1016/j.jconrel.2006.01.00510.1016/j.jconrel.2006.01.005 ↗
28. 10.1002/wnan.133910.1002/wnan.1339 ↗
29. 10.1002/cncr.2273910.1002/cncr.22739 ↗
30. 10.1056/NEJMc05288010.1056/NEJMc052880 ↗
31. 10.3390/antib904005310.3390/antib9040053 ↗
32. 10.1038/nri284910.1038/nri2849 ↗
33. 10.1038/nri79910.1038/nri799 ↗
34. 10.1038/nri338310.1038/nri3383 ↗
35. 10.1002/JLB.3RI0519-161R10.1002/JLB.3RI0519-161R ↗
36. 10.4049/jimmunol.160.12.597910.4049/jimmunol.160.12.5979 ↗
37. 10.4049/jimmunol.161.8.409110.4049/jimmunol.161.8.4091 ↗
38. 10.1126/science.aaz542510.1126/science.aaz5425 ↗
39. 10.1073/pnas.190184111610.1073/pnas.1901841116 ↗
40. Langereis J. D. · Infect. Immun. · 2019 · 87
41. 10.1002/eji.20184770710.1002/eji.201847707 ↗
42. 10.1038/nnano.2016.26910.1038/nnano.2016.269 ↗
43. 10.1038/s41565-018-0344-310.1038/s41565-018-0344-3 ↗
44. 10.1016/j.addr.2020.07.02410.1016/j.addr.2020.07.024 ↗
45. 10.1128/IAI.72.4.2148-2151.200410.1128/IAI.72.4.2148-2151.2004 ↗
46. 10.1016/S0165-5728(02)00139-X10.1016/S0165-5728(02)00139-X ↗
47. 10.1016/S0165-5728(00)00461-610.1016/S0165-5728(00)00461-6 ↗
48. 10.1002/(SICI)1097-4547(19980115)51:2<237::AID-JNR12>3.0.CO;2-510.1002/(SICI)1097-4547(19980115)51:2<237::AID-JNR12>3.0.CO;2-5 ↗
49. 10.1016/S0022-3565(24)35391-110.1016/S0022-3565(24)35391-1 ↗
50. 10.1016/j.ijpharm.2014.09.04710.1016/j.ijpharm.2014.09.047 ↗
51. 10.1038/ni125610.1038/ni1256 ↗
52. 10.1208/s12249-018-1120-210.1208/s12249-018-1120-2 ↗
53. 10.1007/s11095-012-0934-y10.1007/s11095-012-0934-y ↗
54. Zhao Y. · Int. J. Nanomed. · 2012 · 7 · 2891
55. 10.1016/j.jconrel.2018.08.02210.1016/j.jconrel.2018.08.022 ↗
56. 10.1016/j.taap.2014.03.00210.1016/j.taap.2014.03.002 ↗
57. 10.1016/j.jconrel.2006.08.00110.1016/j.jconrel.2006.08.001 ↗
58. 10.1016/j.jconrel.2007.11.00910.1016/j.jconrel.2007.11.009 ↗
59. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
60. 10.1016/j.jconrel.2021.12.02510.1016/j.jconrel.2021.12.025 ↗
61. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
62. 10.1021/bp049840y10.1021/bp049840y ↗
63. 10.1002/jps.2399410.1002/jps.23994 ↗
64. 10.1016/j.eplepsyres.2014.01.01010.1016/j.eplepsyres.2014.01.010 ↗
65. 10.1039/C5CS00217F10.1039/C5CS00217F ↗
66. 10.1038/nnano.2012.23710.1038/nnano.2012.237 ↗
67. 10.1158/0008-5472.CAN-05-419910.1158/0008-5472.CAN-05-4199 ↗
68. 10.1021/acs.molpharmaceut.8b0061210.1021/acs.molpharmaceut.8b00612 ↗
69. 10.1039/c3cc37307j10.1039/c3cc37307j ↗
70. 10.1016/j.apsb.2021.09.02410.1016/j.apsb.2021.09.024 ↗
71. 10.1186/s13046-019-1123-110.1186/s13046-019-1123-1 ↗
72. Gabizon A. · Clin. Cancer Res. · 2003 · 9 · 6551
73. 10.1021/acs.molpharmaceut.1c0052510.1021/acs.molpharmaceut.1c00525 ↗
74. 10.1021/acsnano.0c0282110.1021/acsnano.0c02821 ↗
75. 10.1186/ar450010.1186/ar4500 ↗
76. 10.1186/ar186110.1186/ar1861 ↗
77. 10.1007/s10875-012-9783-z10.1007/s10875-012-9783-z ↗
78. 10.7150/thno.2216410.7150/thno.22164 ↗
79. 10.1016/j.semcdb.2017.06.00910.1016/j.semcdb.2017.06.009 ↗
80. 10.1021/acsnano.9b0721810.1021/acsnano.9b07218 ↗
81. 10.1016/j.jconrel.2021.11.04210.1016/j.jconrel.2021.11.042 ↗
82. 10.3390/molecules2307170010.3390/molecules23071700 ↗
83. 10.1016/j.jconrel.2014.08.00910.1016/j.jconrel.2014.08.009 ↗
84. 10.1016/j.molimm.2014.06.03810.1016/j.molimm.2014.06.038 ↗
85. 10.1016/j.jconrel.2017.11.04310.1016/j.jconrel.2017.11.043 ↗
86. 10.1016/j.ymthe.2021.01.03010.1016/j.ymthe.2021.01.030 ↗
87. 10.1111/all.1479410.1111/all.14794 ↗
88. 10.1200/JCO.2007.13.660610.1200/JCO.2007.13.6606 ↗
89. 10.1021/acsnano.9b0394210.1021/acsnano.9b03942 ↗
90. 10.1016/j.jaci.2015.10.03510.1016/j.jaci.2015.10.035 ↗
91. 10.1016/j.clim.2018.11.00710.1016/j.clim.2018.11.007 ↗
92. Schwarz J. A. · Verh. Dtsch. Ges. Inn. Med. · 1975 · 81 · 1226
93. 10.1002/art.2305910.1002/art.23059 ↗
94. 10.1186/s12969-019-0365-y10.1186/s12969-019-0365-y ↗
95. 10.3389/fimmu.2021.67164810.3389/fimmu.2021.671648 ↗
96. Tavares A. J. · Proc. Natl. Acad. Sci. U. S. A. · 2017 · 114
97. 10.1016/0304-4165(81)90259-210.1016/0304-4165(81)90259-2 ↗
98. 10.1084/jem.117.1.13910.1084/jem.117.1.139 ↗
99. 10.1126/science.683629410.1126/science.6836294 ↗
100. 10.1016/j.bbagen.2013.01.02110.1016/j.bbagen.2013.01.021 ↗